Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer (NCT05950945)
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Who can join: Review the eligibility criteria below.
Location: Mount Sinai Medical Center — Miami Beach, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (88 Sites)
Showing the first 25 of 88 sites.
- Mount Sinai Medical Center — Miami Beach, Florida
- USF College of Medicine — Tampa, Florida
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Beth Israel Lahey Health — Burlington, Massachusetts
- Overlook Medical Center — Summit, New Jersey
- Mater Hospital Sydney — North Sydney, New South Wales
- Monash Medical Centre Moorabbin — East Bentleigh, Victoria
- GenesisCare St Andrews Hospital — Adelaide,
- Fiona Stanley Hospital — Murdoch,
- Institut Jules Bordet — Anderlecht,
- GZA Ziekenhuizen — Antwerp,
- Universitair Ziekenhuis Brussel — Brussels,
- Cliniques Universitaires Saint-Luc — Brussels,
- UZ Leuven — Leuven,
- Centre Hospitalier Universitaire de Liege Sart-Tilman — Liège,
- GZA Ziekenhuizen — Wilrijk,
- Centro de Oncologia - Unidade Brasília - Hospital Sírio Libanês — Brasília,
- CIONC-Centro Integrado de Oncologia de Curitiba — Curitiba,
- Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer — Curitiba,
- CEPON - Centro de Pesquisas Oncológicas de Santa Catarina — Florianópolis,
- Oncosite - Centro de Pesquisa Clinica e Oncologia — Ijuí,
- Fundação Doutor Amaral Carvalho — Jaú,
- Instituto de Cancer de Londrina — Londrina,
- Hospital das Clínicas FMRP-USP — Riberão Preto,
- Hospital Nossa Senhora da Conceicao — Rio Grande,
📞 Contact the Study Coordinator
Phone: (908) 992-6400
Email: CTRinfo@dsi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.